Medibiofarma

medibiofarma.com ↗ ·Noáin ·Seed

Medibiofarma is a Spanish clinical-stage biotechnology company founded in 2016 by a team of drug-discovery veterans linked to Palobiofarma, specialising in target-based medicinal chemistry and small molecules for high-unmet-need diseases. Its pipeline covers fibrotic Crohn's disease and inflammatory bowel disease (lead asset MBF-118, a PPARγ covalent partial agonist that completed a Phase IIa trial in 2025), plus oncology (T-cell infiltration) and neurodegeneration (e.g. Huntington's); asset MBF-015 received the European Commission Seal of Excellence and the Crohn's & Colitis Foundation's IBD Ventures programme has funded MBF-118 twice (2023 and August 2025). It is headquartered in Noáin/Cordovilla, Navarra, and is very small (~10 staff).

Founded

2016

Founders

Total funds raised

€4.8M

SectorsBiotech, Pharmaceuticals, Drug Discovery, Healthtech & Bio Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Julio Castro-Palomino

Co-founder

Also at Palobiofarma

Rodolfo Rodríguez Iglesias

Co-founder & IP Director

Global models 5

Nimbus Therapeutics

United States · www.nimbustx.com ↗

Private biotech that designs small-molecule drugs against chosen targets for immune and inflammatory diseases and makes money by licensing or selling its drug candidates, as Medibiofarma aims to.

~$600MComparable

Pliant Therapeutics

United States · pliantrx.com ↗

Clinical-stage biotech developing oral small molecules against fibrosis, the same target area as Medibiofarma's lead drug for fibrotic Crohn's disease.

~$200MComparable

Ventyx Biosciences

United States · ventyxbio.com ↗

Clinical-stage biotech developing oral small-molecule drugs for inflammatory bowel disease and other inflammatory conditions.

~$170MComparable

Morphic Therapeutic

United States · morphictx.com ↗

VC-backed biotech that took an oral small-molecule drug for inflammatory bowel disease into clinical trials and was later acquired by Eli Lilly, the exit route Medibiofarma's model points to.

~$130MComparable

Landos Biopharma

United States · landosbiopharma.com ↗

Clinical-stage biotech developing oral small molecules for Crohn's disease and ulcerative colitis, including drugs that act on PPAR-related pathways like Medibiofarma's MBF-118.

~$100MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 5

Open as list →

Sodena

www.sodena.com

4 rounds · 2019–24 Spain

Inveready

inveready.com

2 rounds · 2022–24 Spain

Fitalent

fitalent.com

Seed 2022 Spain

Centro para el Desarrollo Tecnológico y la Innovación

www.cdti.es

Investor Spain

Darpaufarma

Investor Spain

Funding rounds 4

·2 not counted

Date	Round	Amount	Lead
2024-04-03	Seed (estimated)	€1M	Lead not disclosed +2 more
2022-03-15	Seed (estimated)	€1.2M	Lead not disclosed +3 more
2021-04-22	Seed (estimated)	€615K	Lead not disclosed +1 more
2019-04-02	Seed (estimated)	€2M	Lead not disclosed +1 more

Not counted (2)

Not counted in totals

2022-03-15	Public Loan	€500K	ENISA
2021-04-22	Grant	€800K	Lead unknown

News 6

Open as list →

Published	Article
2026-06-11	Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women's health pipeline ↗ GlobeNewswire 2026-06-11
2026-01-22	Asabys-backed Oriva Therapeutics launches to advance novel treatments for women's health ↗ Biotech Spain 2026-01-22
2025-08-28	Medibiofarma Successfully Completes Phase 2A Clinical Trial of MBF-118 for Fibrotic Crohn's Disease ↗ Medibiofarma (press release) 2025-08-28
2025-08-25	Medibiofarma Receives 2nd Funding Award from the Crohn's & Colitis Foundation to Support Development of a New Antifibrotic Therapy ↗ Biotech Spain 2025-08-25
2025-02-27	Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain ↗ Palobiofarma (press release) 2025-02-27
2024-03-11	First patient dosed in the Phase IIa clinical trial of MBF-015 in patients with Huntington's disease ↗ Medibiofarma (press release) 2024-03-11